Pharma Focus Asia

Beactica Signs Three-Year Extension Agreement With Sanofi

Monday, May 28, 2018

Beactica, the Swedish drug discovery company with world-leading expertise in molecular interactions, today announced that it has signed a three-year extension of its master services agreement with Sanofi. The agreement outlines the legal terms under which Beactica and Sanofi collaborate on the characterization of interactions between novel therapeutics and their target proteins.

As part of the collaboration, Beactica scientists have supported Sanofi with analysis of the interaction kinetics between insulin analogues and their two binding sites on the full-length insulin receptor. Results from the collaboration contributed towards the regulatory approval of Insulin lispro Sanofi®, a rapid-acting insulin biosimilar recently introduced on the market by Sanofi.

"We are pleased to extend our agreement with Sanofi and look forward to continuing our fruitful collaboration." said Dr Per Källblad, CEO of Beactica. "It is very rewarding to see tangible evidence on how Beactica's expertise and capabilities contribute towards products that increase the quality of life for patients living with compromised health conditions."

Beactica has established relationships with several global top-20 pharmaceutical companies as well as a growing number of biotech companies. The collaboration with Sanofi is ongoing since 2015.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024